[go: up one dir, main page]

BR9711881A - Cepas atenuadas de microorganismos que expressam proteìnas de hpv. - Google Patents

Cepas atenuadas de microorganismos que expressam proteìnas de hpv.

Info

Publication number
BR9711881A
BR9711881A BR9711881-8A BR9711881A BR9711881A BR 9711881 A BR9711881 A BR 9711881A BR 9711881 A BR9711881 A BR 9711881A BR 9711881 A BR9711881 A BR 9711881A
Authority
BR
Brazil
Prior art keywords
hpv
microorganisms
express
attenuated
hpv proteins
Prior art date
Application number
BR9711881-8A
Other languages
English (en)
Inventor
Denise Nardelli Haefliger
Jean-Pierre Kraehenbuhl
Original Assignee
Fondation Pour Le Perfectionne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondation Pour Le Perfectionne filed Critical Fondation Pour Le Perfectionne
Publication of BR9711881A publication Critical patent/BR9711881A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

''CEPAS ATENUADAS DE MICROORGANISMOS QUE EXPRESSAM PROTEìNAS DE HPV''. Este pedido de patente refere-se ao uso de cepas atenuadas de microorganismos procorióticos (tal como Salmonella) que expressam o ácido nucléico que codifica as proteínas do HPV como vacinas contra infecção por HPV e contra o aumento do risco de câncer associado a ela. Particularmente, o trabalho demonstra que é possível agregar VLPs em um organismo procariótico e que a imunização nasal de camudongos com as cepas provoca o aparecimento de anticorpos neutralizadores conformacionalmente dependentes e específicos ao HPV no soro e nas secreções genitais. Os exprerimentos aqui descrito demonstram que tambem é possível agregar VLPs quiméricas de um HPV que incluam um parceiro de fusão e que a proteção de tumores pode ser induzida.
BR9711881-8A 1996-10-09 1997-10-07 Cepas atenuadas de microorganismos que expressam proteìnas de hpv. BR9711881A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9621091.9A GB9621091D0 (en) 1996-10-09 1996-10-09 Attenuated microorganisms strains and their uses
PCT/GB1997/002740 WO1998015631A1 (en) 1996-10-09 1997-10-07 Attenuated microorganism strains expressing hpv proteins

Publications (1)

Publication Number Publication Date
BR9711881A true BR9711881A (pt) 2000-01-18

Family

ID=10801186

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711881-8A BR9711881A (pt) 1996-10-09 1997-10-07 Cepas atenuadas de microorganismos que expressam proteìnas de hpv.

Country Status (8)

Country Link
US (4) US6458368B1 (pt)
EP (1) EP0932683A1 (pt)
JP (1) JP2001506844A (pt)
AU (1) AU730733B2 (pt)
BR (1) BR9711881A (pt)
CA (1) CA2268283A1 (pt)
GB (1) GB9621091D0 (pt)
WO (1) WO1998015631A1 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1160469C (zh) * 1994-12-09 2004-08-04 帝国大学改革有限公司 基因的鉴定
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
AU749695B2 (en) * 1997-09-10 2002-07-04 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JP4563582B2 (ja) * 1998-08-14 2010-10-13 メルク・シャープ・エンド・ドーム・コーポレイション ヒトパピローマウイルスのウイルス様粒子を使用するタンパク質送達系
US6936425B1 (en) * 1998-09-04 2005-08-30 Microscience Limited Attenuated salmonella SP12 mutants as antigen carriers
RU2245163C2 (ru) 1998-11-30 2005-01-27 Сайтос Байотекнолэджи АГ Композиция (варианты), способ получения не природной упорядоченной и содержащей повторы антигенной матрицы, способ терапевтического лечения и способ иммунизации
DK1135025T3 (da) * 1998-12-02 2007-08-13 Univ Maryland Plasmidstabiliseringssystem til antigen administration
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
DE60011560T2 (de) * 1999-12-28 2005-08-18 Akzo Nobel N.V. Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
US20040214158A1 (en) * 2000-05-12 2004-10-28 Neerja Sethi Treatment of human papillomavirus (hpv)-infected cells
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
JP4516748B2 (ja) 2001-09-14 2010-08-04 サイトス バイオテクノロジー アーゲー ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
ES2323634T5 (es) * 2002-05-17 2012-09-04 University Of Cape Town Proteínas quiméricas l1 del virus del papiloma humano 16 que contienen un péptido l2, partículas tipo virus preparadas a partir de estas proteínas y un método para preparar las partículas
CN102061288A (zh) 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
EP1523334A2 (en) 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-carrier conjugates and uses thereof
AU2003250110C1 (en) 2002-07-19 2008-05-29 Novartis Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
CN1820020B (zh) * 2003-05-06 2010-04-28 技术持有有限公司 Sars-冠状病毒病毒样颗粒以及应用方法
PL1576967T3 (pl) * 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
WO2005123762A2 (en) * 2004-06-18 2005-12-29 Indian Immunologicals Ltd Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16
NZ561040A (en) 2005-03-18 2009-04-30 Cytos Biotechnology Ag Cat allergen fusion proteins and use thereof
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP1931383A1 (en) 2005-09-28 2008-06-18 Cytos Biotechnology AG Interleukin-1 conjugates and uses thereof
WO2007068747A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
TWI321350B (en) * 2006-04-18 2010-03-01 Advanced Semiconductor Eng Heatsink and heatsink positioning system
PL2032592T3 (pl) 2006-06-12 2013-11-29 Kuros Biosciences Ag Sposoby pakowania oligonukleotydów do cząstek wirusopodobnych z bakteriofagów RNA
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009158240A1 (en) 2008-06-16 2009-12-30 Emergent Product Development Uk Limited Salmonella vectored vaccines against chlamydia and methods of use
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
CA2744754A1 (en) 2008-12-09 2010-06-17 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
NZ618391A (en) 2009-07-30 2015-07-31 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
CN104548089B (zh) 2009-09-03 2017-09-26 辉瑞疫苗有限责任公司 Pcsk9疫苗
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
KR101349291B1 (ko) 2010-08-10 2014-01-10 한국생명공학연구원 고초균을 이용하여 자궁경부암 백신을 제조하는 방법
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
EP2831225A1 (en) 2012-03-26 2015-02-04 The United States of America, As Represented by the Secretary, Dept. of Health & Human Services Office of Technology Transfer Delivery of packaged rna to mammalian cells
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2801364A1 (en) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonella strain for use in the treatment and/or prevention of cancer
SG11201604868YA (en) 2013-12-16 2016-07-28 Us Health Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
CN119286871A (zh) 2018-04-19 2025-01-10 查美特制药公司 合成rig-i样受体激动剂
EP4048795A1 (en) 2019-10-23 2022-08-31 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
WO2021250628A1 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Bacterial immunization using nanoparticle vaccine
US20220241400A1 (en) * 2021-02-02 2022-08-04 Provaxus, Inc. Immunomodulation platform and methods of use
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2524487B1 (fr) 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
CA1276575C (fr) 1984-11-30 1990-11-20 Sylvie Beaudenon Sondes a papillomavirus et procede de diagnostic in vitro d'infections a papillomavirus
US5411857A (en) 1985-07-31 1995-05-02 Institut Nationale De La Sante Probes for papillomaviruses and an in vitro diagnostic procedure for papilloma infections
JP2648303B2 (ja) 1985-04-04 1997-08-27 ジョージタウン・ユニバーシティ 型特異的乳頭腫ウイルスｄｎａ配列およびペプチド
FR2586428B1 (fr) 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
DE3625257A1 (de) 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
US5447839A (en) 1988-09-09 1995-09-05 Hoffmann-La Roche Inc. Detection of human papillomavirus by the polymerase chain reaction
SE8803870D0 (sv) 1988-10-28 1988-10-28 Medscand Ab Method for detection of human papillomavirus (hpv) for diagnostic purposes
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
CA2038581A1 (en) 1990-03-20 1991-09-21 Martin Muller Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
SE9001705D0 (sv) 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
FR2661921B1 (fr) 1990-05-11 1992-08-07 Pasteur Institut Sonde a papillomavirus (hpv66), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus.
JP3601602B2 (ja) * 1990-11-09 2004-12-15 ワシントン ユニバーシティ 無毒性微生物及びその使用：サルモネラ
FR2670797A1 (fr) 1990-12-20 1992-06-26 Pasteur Institut Sequences d'adn determinees derivees du genome du papillomavirus hpv39, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus, et a la production de composition immunogene.
DE9106105U1 (de) 1991-05-17 1991-09-26 Behringwerke Ag, 3550 Marburg Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen
GB9113809D0 (en) 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DK1359156T3 (da) 1991-07-19 2007-04-10 Univ Queensland Vaccine mod humanpapillomavirus
WO1994000152A1 (en) 1992-06-25 1994-01-06 Georgetown University Papillomavirus vaccines
ES2127829T3 (es) * 1992-07-31 1999-05-01 Medeva Holdings Bv Expresion de proteinas recombinantes fusionadas en bacterias atenuadas.
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
GB9304239D0 (en) 1993-03-01 1993-04-21 British Bio Technology Viral particles
GB9306731D0 (en) 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
GB9313556D0 (en) 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
AUPM358894A0 (en) 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
PT757717E (pt) 1994-05-16 2006-09-29 Merck & Co Inc Vacinas de papilomavirus
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
CZ87597A3 (cs) 1994-09-22 1998-01-14 Merck And Co., Inc. Molekula DNK kódující lidský papilomavirus typu 6A a použití této molekuly
GB9420146D0 (en) 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
AU4270196A (en) 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
WO1996026277A1 (en) 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5795754A (en) 1995-07-19 1998-08-18 Merck & Co., Inc. Synthetic HPV11 virus-like particles
US5738853A (en) 1995-11-15 1998-04-14 Merck & Co., Inc. Synthetic HPV11 virus-like particles
FR2749323B1 (fr) 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US5879764A (en) 1996-11-06 1999-03-09 W. R. Grace & Co.-Conn. Desiccation using polymer-bound desiccant beads
CA2275259C (en) 1996-12-20 2008-02-12 Merck & Co., Inc. Formulations of recombinant papillomavirus vaccines
DE19712541C1 (de) 1997-03-25 1998-11-05 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen

Also Published As

Publication number Publication date
WO1998015631A1 (en) 1998-04-16
CA2268283A1 (en) 1998-04-16
JP2001506844A (ja) 2001-05-29
GB9621091D0 (en) 1996-11-27
AU4566897A (en) 1998-05-05
AU730733B2 (en) 2001-03-15
US6458368B1 (en) 2002-10-01
US6251406B1 (en) 2001-06-26
US20040115212A1 (en) 2004-06-17
US20010029043A1 (en) 2001-10-11
EP0932683A1 (en) 1999-08-04
US20020025328A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
BR9711881A (pt) Cepas atenuadas de microorganismos que expressam proteìnas de hpv.
CO5070644A1 (es) Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante
EP1016418A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
GR3035245T3 (en) Protein targeting into hiv virions based on hiv-1 vpr fusion molecules
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
ZA9510832B (en) Variants of human papilloma virus antigens
ES2129386T3 (es) Vacuna contra la gripe.
IL144371A0 (en) Her-2/neu fusion proteins
EP1465990A4 (en) LYSOSTAPHINE TRUNCATED MOLECULE WITH IMPROVED STAPHYLOLYTIC ACTIVITY
WO2000014244A3 (en) Treatment of cervical cancer
DK1252322T3 (da) Herpesvirusstamme til genterapi
KR930700143A (ko) B형 간염 백신
PT1212358E (pt) Genes sinteticos de papilomavirus humano
BR0014408A (pt) Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos
BR9609072A (pt) Fatores de ativação macrófagos derivados de proteìna ligada a vitamina d clonada
WO2001087350A3 (en) Treatment of human papillomavirus (hpv)-infected cells
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
EP1934246B8 (en) Matrix metalloproteinase 11 vaccine
Arme et al. Observations on a tissue response within the body cavity of fish infected with the plerocercoid larvae of Ligula intestinalis (L.)(Cestoda: Pseudophyllidea)
CN102286490B (zh) 一种鸡干扰素γ的制备复性方法
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
KR950704498A (ko) 키틴 탈아세틸화제를 코드화하는 dna(dna encoding chitin deacetylase)
BR9910594A (pt) Vìrus de herpes simplex, uso de um vìrus de herpessimplex, composição farmacêutica e processospara estudar a função de um gene heterólogo emuma célula de mamìfero, para produzir um vìrus deherpes simplex e para tratar um distúrbio ou uma lesãodo sistema nervoso de um mamìfero
AU1948788A (en) Expression of immunologically active proteins of human b-lymphotropic virus
BR112021023483A2 (pt) Novo anticorpo anti-vírus da hepatite b e seus usos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]